Literature DB >> 25087900

Are alternative donors really still "alternative?".

Christopher G Kanakry1, Leo Luznik2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25087900      PMCID： PMC4596228          DOI： 10.1016/j.bbmt.2014.07.029

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  28 in total

Review 1.  Effect of HLA mismatches on the outcome of hematopoietic transplants.

Authors:  E W Petersdorf; E M Mickelson; C Anasetti; P J Martin; A E Woolfrey; J A Hansen
Journal:  Curr Opin Immunol       Date:  1999-10       Impact factor: 7.486

2.  Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.

Authors:  Claudio G Brunstein; Jonathan A Gutman; Daniel J Weisdorf; Ann E Woolfrey; Todd E Defor; Theodore A Gooley; Michael R Verneris; Frederick R Appelbaum; John E Wagner; Colleen Delaney
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

3.  Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors.

Authors:  David I Marks; Kwang Ahn Woo; Xiaobo Zhong; Frederick R Appelbaum; Veronika Bachanova; Juliet N Barker; Claudio G Brunstein; John Gibson; Partow Kebriaei; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Joseph Pidala; Bipin Savani; Vanderson Rocha; Mary Eapen
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

4.  Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia.

Authors:  Régis Peffault de Latour; Claudio G Brunstein; Raphael Porcher; Patrice Chevallier; Marie Robin; Erica Warlick; Alienor Xhaard; Celalettin Ustun; Jérôme Larghero; Nathalie Dhedin; Mohamad Mohty; Gerard Socié; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-18       Impact factor: 5.742

5.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Authors:  Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

6.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

Authors:  Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

7.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.

Authors:  Mary Eapen; Pablo Rubinstein; Mei-Jie Zhang; Cladd Stevens; Joanne Kurtzberg; Andromachi Scaradavou; Fausto R Loberiza; Richard E Champlin; John P Klein; Mary M Horowitz; John E Wagner
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

8.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Authors:  Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

9.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

10.  Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood.

Authors:  Celso Arrais Rodrigues; Vanderson Rocha; Peter Dreger; Claudio Brunstein; Henrik Sengeloev; Jürgen Finke; Mohamad Mohty; Bernard Rio; Eefke Petersen; François Guilhot; Dietger Niederwieser; Jan J Cornelissen; Pavel Jindra; Arnon Nagler; Nathalie Fegueux; Hélène Schoemans; Stephen Robinson; Annalisa Ruggeri; Eliane Gluckman; Carmen Canals; Anna Sureda
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941
View more
  2 in total

1.  Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.

Authors:  Bipin N Savani; Myriam Labopin; Nicolaus Kröger; Jürgen Finke; Gerhard Ehninger; Dietger Niederwieser; Rainer Schwerdtfeger; Donald Bunjes; Bertram Glass; Gerard Socié; Per Ljungman; Charles Craddock; Frédéric Baron; Fabio Ciceri; Norbert Claude Gorin; Jordi Esteve; Christoph Schmid; Sebastian Giebel; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

Review 2.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.